Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director | June 14, 2023 | June 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,575 |
Reported balance
After 2023-06-14 transaction · row 1
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 6,500 · Balance 31,575 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2023 Filed Jun 16, 2023 20:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-003962 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,575 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:15 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 7,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-004297 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,075 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2023 annual meeting of the Company's stockholders or June 8, 2023. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 13:00 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 2,000 | $24.66 | $49,318.00 |
DisclosureSEC source: 0001171843-22-001878 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,121 F1 · price: On March 11, 2022, Mr. Thompson purchased 2,000 shares in multiple trades ranging from $24.53 to $24.70. The price reported above reflects the weighted average purchase price. Mr. Thompson undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:19 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-004430 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,121 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2022 annual meeting of the Company's stockholders or June 16, 2022. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001356 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,949 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 25, 2021. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 20:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 4,843 | $56.66 | $274,404.38 |
DisclosureSEC source: 0001171843-19-005414 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,842 F1 · price: Represents the weighted average sales price. The shares were sold on 8/8/19 at prices ranging from $56.65 to $56.75 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:36 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001391 · ownership.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,685 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 1,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-000696 · formfour.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,843 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 24, 2019. Read SEC document |
| May 22, 2017 Filed May 23, 2017 20:56 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 9,628 | $47.37 | $456,078.36 |
DisclosureSEC source: 0001171843-17-003274 · formfour.xml · nonDerivative · entry 2 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,217 F2 · price: Represents the weighted average sales price. The shares were sold on 5/22/2017 at prices ranging from $47.25 to $47.45 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| May 19, 2017 Filed May 23, 2017 20:56 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 1,097 | $47.58 | $52,195.26 |
DisclosureSEC source: 0001171843-17-003274 · formfour.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,845 F1 · price: Represents the weighted average sales price. The shares were sold on 5/19/2017 at prices ranging from $47.56 to $47.61 per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 1,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-17-000591 · formfour.xml · nonDerivative · entry 1 Thompson Jeffery S · CIK 0001510398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,942 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.